Terms: = Kidney tumors AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679
214 results:
1. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract] [Full Text] [Related]
2. 18 F-PSMA-1007 PET/CT in a Case of Von Hippel-Lindau Syndrome.
Dong A; Zhao B; Wang L; Cheng C; Zuo C
Clin Nucl Med; 2023 Dec; 48(12):e600-e602. PubMed ID: 37844561
[TBL] [Abstract] [Full Text] [Related]
3. Phase I clinical evaluation of
Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V
Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776
[TBL] [Abstract] [Full Text] [Related]
4. [
Lin R; Wang C; Chen S; Lin T; Cai H; Chen S; Yang Y; Zhang J; Xu F; Zhang J; Chen X; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):535-547. PubMed ID: 37728667
[TBL] [Abstract] [Full Text] [Related]
5. TGMIL: A hybrid multi-instance learning model based on the Transformer and the Graph Attention Network for whole-slide images classification of renal cell carcinoma.
Sun X; Li W; Fu B; Peng Y; He J; Wang L; Yang T; Meng X; Li J; Wang J; Huang P; Wang R
Comput Methods Programs Biomed; 2023 Dec; 242():107789. PubMed ID: 37722310
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of cMYC-max transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma.
Li W; Bano F; Khan A; Wei DQ; Alshammari A; Xu B; Wang Y
Comput Biol Med; 2023 Sep; 164():107257. PubMed ID: 37527610
[TBL] [Abstract] [Full Text] [Related]
7. Role of 18 F-FDG PET/CT in the diagnosis of benign vs. malignant tumor thrombus.
Sarswat S; Khan D; Sagar S; Kumar R
Nucl Med Commun; 2023 Aug; 44(8):726-731. PubMed ID: 37272295
[TBL] [Abstract] [Full Text] [Related]
8. Volumetric Analysis of Renal Masses as Predictors of Partial Nephrectomy Outcomes.
Das H; Fudge T; Hernandez B; McGregor TB; Kirkpatrick IDC; Kaushik D; Mansour AM; Svatek RS; Liss MA; Gelfond J; Pruthi DK
J Endourol; 2023 Jun; 37(6):673-680. PubMed ID: 37166349
[No Abstract] [Full Text] [Related]
9. A case report of hepatic angiomyolipoma, inflammatory subtype. Clinico-pathological characterization: a diagnostic challenge.
Velasco-Albendea FJ; Gil-Belmonte MJ; Estébanez-Ferrero B; Fuentes-Porcel O; Nievas-Soriano BJ
Diagn Pathol; 2023 Apr; 18(1):57. PubMed ID: 37118824
[TBL] [Abstract] [Full Text] [Related]
10. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract] [Full Text] [Related]
11. Early Postoperative Outcomes of Retroperitoneal Partial Nephrectomy of Anterior and Posterior Renal tumors: A 5-Year Experience in A Single Center.
Hsieh CC; Tseng WH; Liu CL; Su CC; Li CF; Ho CH; Huang SK; Chiu AW
J Endourol; 2023 May; 37(5):557-563. PubMed ID: 36927036
[No Abstract] [Full Text] [Related]
12. PCGF6/max/KDM5D facilitates MAZ/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter.
Zhu M; Zhang RN; Zhang H; Qu CB; Zhang XC; Ren LX; Yang Z; Gu JF
Epigenetics Chromatin; 2023 Mar; 16(1):9. PubMed ID: 36890610
[TBL] [Abstract] [Full Text] [Related]
13. Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study.
Rossi E; Boldrini L; Maratta MG; Gatta R; Votta C; Tortora G; Schinzari G
Hum Vaccin Immunother; 2023 Dec; 19(1):2172926. PubMed ID: 36723981
[TBL] [Abstract] [Full Text] [Related]
14. Transarterial ethiodised oil marking before CT-guided renal cryoablation: evaluation of tumour visibility in various renal cell carcinoma subtypes.
Tsuji Y; Miura H; Hirota T; Ota Y; Yamashita M; Asai S; Fujihara A; Hongo F; Ukimura O; Yamada K
Clin Radiol; 2023 Apr; 78(4):279-285. PubMed ID: 36710120
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
Arikan R; Ozguven S; Telli TA; Isik S; Demircan NC; Basoglu T; Yasar A; Celebi A; Filizoglu N; Ustun HS; Tinay I; Ones T; Turoglu HT; Erdil TY; Ozturk MA; Ercelep O; Bayoglu V; Kostek O; Dane F; Yumuk PF
Acta Radiol; 2023 May; 64(5):2040-2049. PubMed ID: 36447438
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous Renal Cell Carcinoma Metastases.
Dove APH; Wells A; Gong W; Liu D; Kirschner AN
Am J Clin Oncol; 2022 Dec; 45(12):501-505. PubMed ID: 36413679
[TBL] [Abstract] [Full Text] [Related]
17. Interstitial Brachytherapy of the Liver for Renal Cell Carcinoma: ADC Measurements Do Not Predict Overall Survival.
Thormann M; Heitmann F; Wrobel V; March C; Pech M; Surov A; Damm R; Omari J
In Vivo; 2022; 36(6):2945-2951. PubMed ID: 36309358
[TBL] [Abstract] [Full Text] [Related]
18. A Von Hippel-Lindau Disease-Associated Microcystic Adenoma of the Ethmoid Sinus Mimicking Metastatic Clear Cell Renal Cell Carcinoma.
Tsukamoto S; Koyasu S; Sugimoto A; Matsunaga M; Nakamoto Y
Clin Nucl Med; 2023 Feb; 48(2):194-196. PubMed ID: 36179325
[TBL] [Abstract] [Full Text] [Related]
19.
Tzortzakakis A; Papathomas T; Gustafsson O; Gabrielson S; Trpkov K; Ekström-Ehn L; Arvanitis A; Holstensson M; Karlsson M; Kokaraki G; Axelsson R
Scand J Urol; 2022; 56(5-6):375-382. PubMed ID: 36065481
[TBL] [Abstract] [Full Text] [Related]
20. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
Hardiansyah D; Riana A; Beer AJ; Glatting G
Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
[TBL] [Abstract] [Full Text] [Related]
[Next]
